.jpg)
For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty
To innovators in the cell and gene therapy field, Peter Marks’ exit from the FDA means losing a seasoned regulator and key ally.
To innovators in the cell and gene therapy field, Peter Marks’ exit from the FDA means losing a seasoned regulator and key ally.
